1.     国家自然科学基金青年基金，NO. 6507047557, 2023.01-2025.12 （主持，在研，纵向）；

2.    抗肿瘤药物ZJ-03开发临床前研究，NO. 8507048497，2023.04-2025.04（唯一完成人，在研，横向）；

3.    抗肿瘤药物YJ-ZD-007开发临床前研究， NO.8507048537，2024.04-2026.04（主持，在研，横向）；

4.    新型活性失踪探针（红色）的设计合成与性质研究，NO. 8507048538，2024.05-2026.05（主持，在研，横向）；

5.     诱导肿瘤干细胞分化促进放疗增敏研究，NO. 8507048540， 2024.07-2027.06（主持，在研，横向）；

6.     江苏省科研创新项目, No. KYCX19_0102，2019.05-2020.05（主持，已结题，纵向）。

1. Mingwei Fu, Min Ge, Wanxiang Yang, Chunchen Hu, Xiaowei Li, Yuanjiang Wang*,and Shaohua Gou*. Discovery of a potent and selective celldivision cycle 7 inhibitor from6-(3-fluoropyridin4-yl)thieno[3,2-d]pyrimidin-4(3H)-one derivatives asan orally active antitumor agent. Acta Pharmaceutica Sinica B, 2024,14(2), 893-896.

2. Yuanjiang Wang, Jianluo Zhang, KunLi, Shengjin Xia, and Shaohua Gou*. Multitargeting HDACInhibitors Containing aRAS/RAF Protein Interfering Unit. Journal of Medicinal Chemistry, 2024,67, 2066-2082.

3. Yuanjiang Wang , Yanchang Pan , Zhaodan Lv , Shaohua Gou, Discovery of N-(4-((6-(3,5-Dimethoxyphenyl)-9H-purinederivatives as irreversible covalent FGFR inhibitors, European Journal of Medicinal Chemistry,2024, 271, 116415.

4. Yuanjiang Wang, Kun Li,Wenqing Xu, Shaohua Gou. Design, synthesis, and biological evaluation of aseries of benzofuran[3,2-d]pyrimidine-4(3H)-onederivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors. BioorganicChemistry, 2023, 139, 106759.

5. Xinyi Wang, Yuanjiang Wang*, Shaohua Gou. A platinum(II) complex HY1-Ptovercomes cisplatin-induced resistance and attenuates metastasis of epithelialovarian cancer by cancer cell stemness inhibition. InternationalJournal of Biochemistry and Cell Biology, 2023, 157,106395.

6. Yanliang Guo, Biao Gao, Peng Gao, Yuanjiang Wang*, Shaohua Gou. Design, synthesis and biological evaluation of phosphoroxy quinazolinederivatives as potential EGFRT790M/C797S inhibitors. Bioorganic& Medicinal Chemistry, 2023, 90, 117338.

7. Xinyi Wang, Zhikun Liu, Yuanjiang Wang*, ShaohuaGou. Platinum(IV) Prodrugs with Cancer Stem Cell Inhibitory Effects on LungCancer for Overcoming Drug Resistance. Journalof Medicinal Chemistry, 2022, 65, 7933-7945.

8. Yuanjiang Wang, Zhaodan Lv, Feihong Chen, Xing Wang, and Shaohua Gou*. Discovery of5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as HighlySelective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition. Journal of Medicinal Chemistry, 2021, 64(8), 5082-5098.

9. Yuanjiang Wang, Xinyi Wang, Gang Xu, and Shaohua Gou*. Novel CK2-Specific Pt(II) Compound ReversesCisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and SuppressingDNA Damage Repair in Non-small Cell Lung Cancer Treatments. Journal of Medicinal Chemistry, 2021,64(7), 4163-4178.

10. Yuanjiang Wang, Zhaodan Lv, Feihong Chen, Xing Wang, and Shaohua Gou*. Conjugates Derived from Lapatinib Derivatives withCancer Cell Stemness Inhibitors Reversed Drug Resistance and SuppressedMigration and Invasion of Triple-negative Breast Cancer. Journalof Medicinal Chemistry, 2021, 64(17), 12877-12892.

11.  Xing Wang1, Yuanjiang Wang1,Shaohua Gou, Feihong Chen*. A trifunctional Pt(II) complex alleviates theNHEJ/HR-related DSBs repairs to evade cisplatin-resistance in NSCLC. BioorganicChemistry, 2020,104, 104210.

1. 2023年荣获东南大学优秀博士学位论文；

招生方向

070300 化学

085602 化学工程 （专业学位）